These patients presented with severe clinical manifestations in accordance with several studies that reported patients had compound heterozygous mutations in AGXT were complained about of severe symptoms such as recurrent urinary tract infections, urolithiasis, nephrocalcinosis with bone deformities, myocardial infiltration, and left ventricular hypertrophy (He et al., 2019, Mbarek et al., 2011). This evidence concerns the gene AGXT and urolithiasis.